



MEDICAL TIPS

TENEBLU Tablets

Issue II, No.5, 2024

Meta-Analysis on the Association between DPP-4 Inhibitors and Bone Mineral Density and Osteoporosis

Huang L, et.al. *J Clin Densitom*; 2024; 27(1): 101455.

- Type 2 diabetes mellitus (T2DM) frequently coexists with osteoporosis and reduced bone mineral density (BMD).
- The present meta-analysis (10 studies, n=214,541) evaluated the impact of dipeptidyl peptidase-4 inhibitors (DPP-4i) on bone health parameters among T2DM patients.
- The use of DPP-4i resulted in a statistically significant increase in BMD in individuals with T2DM.
- The study also showed that using DPP-4i significantly lowers the risk of osteoporosis suggesting its protective role against the development of osteoporosis in T2DM patients.

Dipeptidyl peptidase-4 inhibitors may have a potential positive impact on bone health in T2DM patients

